BEIJING, Oct. 13, 2017 /PRNewswire/ Korea IT Times-- China Biologic Products Holding, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company will host a conference call to discuss the TianXinFu acquisition on Monday, October 16, 2017 before market opens at 8:30 a.m. ET (8:30 p.m. Beijing Time). Listeners may access the call by dialing:

A telephone replay will be available one hour after the conclusion of the conference call through October 23, 2017. The dial-in details are:

A live and archived webcast of the conference call will be available through the Company's investor relations website at http://chinabiologic.investorroom.com/.

About China Biologic Products Holdings, Inc.

China Biologic Products Holdings, Inc. (NASDAQ: CBPO) is a leading fully integrated plasma-based biopharmaceutical company in China. The Company's products are used as critical therapies during medical emergencies and for the prevention and treatment of life-threatening diseases and immune-deficiency related diseases. China Biologic is headquartered in Beijing and manufactures over 20 different dosage forms of plasma products through its majority owned subsidiary, Shandong Taibang Biological Products Co., Ltd., and its wholly owned subsidiary, Guizhou Taibang Biological Products Co., Ltd. The Company also has an equity investment in Xi'an Huitian Blood Products Co., Ltd. The Company sells its products to hospitals, distributors and other healthcare facilities in China. For additional information, please see the Company's website www.chinabiologic.com.

Contact:

China Biologic Products Holdings, Inc.
Mr. Ming Yin
Senior Vice President 
Phone: 
Email: ir@chinabiologic.com

ICR Inc.
Mr. Bill Zima
Phone: or 
E-mail: william.zima@icrinc.com

By Lim Chang-hyun, Beijing Correspondent (info@ko 다른기사 보기